Further Discussions on Monitoring of Burkitt lymphoma

Further discussions with Dr Martin Ogwang and his staff were held in an attempt to determine the cause of the increased mortality during the months following the departure of Dr Calbi. These will not be discussed specfically in the context of Locor, since the data belongs to Lahor, but the problem of increased mortality in general is a central problem to all who treat cancer. Some of the issues that should be considered by hospitals that accept Burkitt lymphoma patients for treatment include 1. Education of all staff members 2. Periodic review of pathology, annual or semi-annual auditing of data collected and intermittent visits after the completion of treatment. This is essential if a figure for long term survival is to be obtained.